Use of open access platforms for clinical trial data

In a study appearing in the March 22/29 issue of JAMA, Ann Marie Navar, M.D., Ph.D., of Duke University Medical Center, Durham, N.C., and colleagues examined how shared clinical trial data are being used. Concerns over bias in clinical trial reporting have stimulated calls for more open data sharing. In response, multiple pharmaceutical companies have created mechanisms for investigators to access patient-level clinical trials data.

The researchers evaluated how many were publicly available to through 3 open access platforms, and found that a total of 3,255 clinical trials were available in the platforms. The median number of trials requested by each proposal was 2. Only 505 unique trials (15.5 percent of available trials) had ever been requested. "Reasons for underutilization of clinical trials data may include lack of knowledge about these resources, possibly due to lack of publication of results from proposals, or lack of funding to support analyses."

"Early use of platforms designed to provide access to individual patient data, developed to increase transparency of , has been limited. Availability of shared clinical trial data should be promoted and use of individual patient data for validation studies encouraged."

Explore further

Reporting of clinical trial results by top academic centers remains poor

More information: JAMA, DOI: 10.1001/jama.2016.2374
Citation: Use of open access platforms for clinical trial data (2016, March 22) retrieved 24 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors